immatics biotechnologies GmbH is a biotechnology business based in the US. immatics biotechnologies GmbH shares (IMTXW) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.01 – an increase of 3.73% over the previous week. immatics biotechnologies GmbH employs 554 staff and has a trailing 12-month revenue of around $155.8 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.01 |
|---|---|
| 52-week range | $0.01 - $4.00 |
| 50-day moving average | $0.00 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | N/A |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0139 from 2025-04-28
| 1 week (2025-04-23) | N/A |
|---|---|
| 1 month (2025-04-04) | -9.74% |
| 3 months (2025-01-31) | -65.25% |
| 6 months (2024-11-04) | -98.60% |
| 1 year (2024-05-02) | -99.45% |
|---|---|
| 2 years (2023-05-03) | -99.43% |
| 3 years (2022-05-03) | 1.61 |
| 5 years (2020-04-30) | N/A |
| Revenue TTM | $155.8 million |
|---|---|
| Operating margin TTM | 1.61% |
| Gross profit TTM | $7.8 million |
| Return on assets TTM | -4% |
| Return on equity TTM | 3.84% |
| Profit margin | 9.77% |
| Book value | $4.73 |
| Market Capitalization | $673 million |
TTM: trailing 12 months
We're not expecting immatics biotechnologies GmbH to pay a dividend over the next 12 months.
Over the last 12 months, immatics biotechnologies GmbH's shares have ranged in value from as little as $0.012 up to $4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while immatics biotechnologies GmbH's is 0.85. This would suggest that immatics biotechnologies GmbH's shares are less volatile than average (for this exchange).
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .